

Niklas Loman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11244126/publications.pdf>

Version: 2024-02-01

78
papers

11,436
citations

94433

37
h-index

76900

74
g-index

80
all docs

80
docs citations

80
times ranked

14710
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Abstract OT2-30-01: Nordictrip, a translational randomized phase-3 study exploring the effect of the addition of capecitabine to carboplatinum-based chemotherapy in early "triple negative" breast cancer, ClinicalTrials.gov Identifier: NCT04335669. Cancer Research, 2022, 82, OT2-30-01-OT2-30-01. | 0.9 | 0 |
| 2 | Abstract P2-08-11: How reliable are biomarkers assessed on a core needle biopsy? A study of paired core needle biopsies and surgical specimens in early breast cancer. Cancer Research, 2022, 82, P2-08-11-P2-08-11. | 0.9 | 0 |
| 3 | Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers. JCO Precision Oncology, 2021, 5, 286-306. | 3.0 | 5 |
| 4 | Preexisting Somatic Mutations of Estrogen Receptor Alpha (<i>ESR1</i>) in Early-Stage Primary Breast Cancer. JNCI Cancer Spectrum, 2021, 5, pkab028. | 2.9 | 20 |
| 5 | Prognostic implications of the expression levels of different immunoglobulin heavy chain-encoding RNAs in early breast cancer. Npj Breast Cancer, 2020, 6, 28. | 5.2 | 25 |
| 6 | Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers. Nature Communications, 2020, 11, 3747. | 12.8 | 53 |
| 7 | Breast cancer survival in Nordic BRCA2 mutation carriers"unconventional association with oestrogen receptor status. British Journal of Cancer, 2020, 123, 1608-1615. | 6.4 | 8 |
| 8 | The mutational landscape of the <i>SCAN</i> "real" world primary breast cancer transcriptome. EMBO Molecular Medicine, 2020, 12, e12118. | 6.9 | 36 |
| 9 | Human G-MDSCs are neutrophils at distinct maturation stages promoting tumor growth in breast cancer. Life Science Alliance, 2020, 3, e202000893. | 2.8 | 14 |
| 10 | Defining the mutational landscape of 3,217 primary breast cancer transcriptomes through large-scale RNA-seq within the Sweden Cancerome Analysis Network: Breast Project (SCAN-B; NCT03430492).. Journal of Clinical Oncology, 2020, 38, 518-518. | 1.6 | 2 |
| 11 | Written pretest information and germline BRCA1/2 pathogenic variant testing in unselected breast cancer patients: predictors of testing uptake. Genetics in Medicine, 2019, 21, 89-96. | 2.4 | 5 |
| 12 | Prediction of Lymph Node Metastasis in Breast Cancer by Gene Expression and Clinicopathological Models: Development and Validation within a Population-Based Cohort. Clinical Cancer Research, 2019, 25, 6368-6381. | 7.0 | 37 |
| 13 | Cross comparison and prognostic assessment of breast cancer multigene signatures in a large population-based contemporary clinical series. Scientific Reports, 2019, 9, 12184. | 3.3 | 39 |
| 14 | Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer. Breast Cancer Research and Treatment, 2019, 178, 459-467. | 2.5 | 23 |
| 15 | Detection of circulating tumor cells and circulating tumor DNA before and after mammographic breast compression in a cohort of breast cancer patients scheduled for neoadjuvant treatment. Breast Cancer Research and Treatment, 2019, 177, 447-455. | 2.5 | 14 |
| 16 | Refinement of breast cancer molecular classification by miRNA expression profiles. BMC Genomics, 2019, 20, 503. | 2.8 | 75 |
| 17 | Maximum Tolerated Dose and Pharmacokinetics of Paclitaxel Micellar in Patients with Recurrent Malignant Solid Tumours: A Dose-Escalation Study. Advances in Therapy, 2019, 36, 1150-1163. | 2.9 | 22 |
| 18 | Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study. Nature Medicine, 2019, 25, 1526-1533. | 30.7 | 218 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancer—an European consensus statement and expert recommendations. <i>European Journal of Cancer</i> , 2019, 106, 54-60. | 2.8 | 25 |
| 20 | High patient satisfaction with a simplified BRCA1/2 testing procedure: long-term results of a prospective study. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 313-318. | 2.5 | 11 |
| 21 | Immune gene expression and response to chemotherapy in advanced breast cancer. <i>British Journal of Cancer</i> , 2018, 118, 480-488. | 6.4 | 37 |
| 22 | Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial. <i>International Journal of Cancer</i> , 2018, 142, 618-628. | 5.1 | 27 |
| 23 | BRCAsearch: written pre-test information and BRCA1/2 germline mutation testing in unselected patients with newly diagnosed breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 117-126. | 2.5 | 14 |
| 24 | Germline mutations in BRCA1 and BRCA2 incidentally revealed in a biobank research study: experiences from re-contacting mutation carriers and relatives. <i>Journal of Community Genetics</i> , 2018, 9, 201-208. | 1.2 | 5 |
| 25 | Clinical Value of RNA Sequencing-Based Classifiers for Prediction of the Five Conventional Breast Cancer Biomarkers: A Report From the Population-Based Multicenter Sweden Cancerome Analysis Network—Breast Initiative. <i>JCO Precision Oncology</i> , 2018, 2, 1-18. | 3.0 | 101 |
| 26 | Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial. <i>Breast Cancer Research</i> , 2018, 20, 48. | 5.0 | 80 |
| 27 | Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer. <i>Oncolmmunology</i> , 2018, 7, e1466017. | 4.6 | 18 |
| 28 | Efficacy versus effectiveness of clinical genetic testing criteria for BRCA1 and BRCA2 hereditary mutations in incident breast cancer. <i>Familial Cancer</i> , 2017, 16, 187-193. | 1.9 | 18 |
| 29 | PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2017, 23, 7225-7231. | 7.0 | 17 |
| 30 | An HIF-1 α /VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression. <i>Cancer Cell</i> , 2017, 32, 669-683.e5. | 16.8 | 352 |
| 31 | Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 117-134. | 2.5 | 18 |
| 32 | Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. <i>Breast Cancer Research</i> , 2016, 18, 112. | 5.0 | 42 |
| 33 | Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. <i>Gynecologic Oncology</i> , 2016, 140, 199-203. | 1.4 | 252 |
| 34 | Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis-Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 146-157. | 7.0 | 38 |
| 35 | The state of the art in prediction of breast cancer relapse using cell-free circulating tumor DNA liquid biopsies. <i>Annals of Translational Medicine</i> , 2016, 4, S68-S68. | 1.7 | 8 |
| 36 | An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2015, 17, 61. | 5.0 | 26 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers. PLoS ONE, 2015, 10, e0120020. | 2.5 | 34 |
| 38 | Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation. Journal of Clinical Oncology, 2015, 33, 244-250. | 1.6 | 1,473 |
| 39 | Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival. Annals of Oncology, 2015, 26, 81-88. | 1.2 | 75 |
| 40 | The Sweden Cancerome Analysis Network - Breast (SCAN-B) Initiative: a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine. Genome Medicine, 2015, 7, 20. | 8.2 | 129 |
| 41 | Clinical Management of Prostate Cancer in Men with BRCA Mutations. European Urology, 2015, 68, 194-195. | 1.9 | 15 |
| 42 | Association of Type and Location of <i>BRCA1</i> and <i>BRCA2</i> Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347. | 7.4 | 390 |
| 43 | Clinical and molecular complexity of breast cancer metastases. Seminars in Cancer Biology, 2015, 35, 85-95. | 9.6 | 118 |
| 44 | DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS Genetics, 2014, 10, e1004256. | 3.5 | 47 |
| 45 | Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2014, 16, 3416. | 5.0 | 57 |
| 46 | Long-term prognosis of early-onset breast cancer in a population-based cohort with a known BRCA1/2 mutation status. Breast Cancer Research and Treatment, 2014, 144, 133-142. | 2.5 | 23 |
| 47 | High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer. Breast Cancer Research and Treatment, 2014, 147, 571-578. | 2.5 | 47 |
| 48 | Impact of the first tumor response at eight weeks on overall survival in metastatic breast cancer patients treated with first-line combination chemotherapy. Medical Oncology, 2013, 30, 415. | 2.5 | 7 |
| 49 | Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial. Breast Cancer Research and Treatment, 2013, 138, 499-508. | 2.5 | 183 |
| 50 | Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. PLoS Genetics, 2013, 9, e1003212. | 3.5 | 244 |
| 51 | The Retinoblastoma Gene Undergoes Rearrangements in <i>BRCA1</i> -Deficient Basal-like Breast Cancer. Cancer Research, 2012, 72, 4028-4036. | 0.9 | 41 |
| 52 | Common Variants at the 19p13.1 and <i>ZNF365</i> Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 645-657. | 2.5 | 47 |
| 53 | Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibition. Cancer Letters, 2012, 319, 232-241. | 7.2 | 45 |
| 54 | Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Research, 2012, 14, R33. | 5.0 | 78 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 55 | Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies. <i>BMC Cancer</i> , 2011, 11, 341. | 2.6 | 76 |
| 56 | Challenges to the Development of New Agents for Molecularly Defined Patient Subsets: Lessons From <i>BRCA1/2</i> -Associated Breast Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 4224-4226. | 1.6 | 23 |
| 57 | Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>Human Molecular Genetics</i> , 2011, 20, 3304-3321. | 2.9 | 68 |
| 58 | Common variants of the <i>BRCA1</i> wild-type allele modify the risk of breast cancer in <i>BRCA1</i> mutation carriers. <i>Human Molecular Genetics</i> , 2011, 20, 4732-4747. | 2.9 | 32 |
| 59 | Identification of New MicroRNAs in Paired Normal and Tumor Breast Tissue Suggests a Dual Role for the <i>ERBB2/Her2</i> Gene. <i>Cancer Research</i> , 2011, 71, 78-86. | 0.9 | 191 |
| 60 | Interplay between <i>BRCA1</i> and <i>RHAMM</i> Regulates Epithelial Apicobasal Polarization and May Influence Risk of Breast Cancer. <i>PLoS Biology</i> , 2011, 9, e1001199. | 5.6 | 91 |
| 61 | A locus on 19p13 modifies risk of breast cancer in <i>BRCA1</i> mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. <i>Nature Genetics</i> , 2010, 42, 885-892. | 21.4 | 309 |
| 62 | Identification of Subtypes in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Reveals a Gene Signature Prognostic of Outcome. <i>Journal of Clinical Oncology</i> , 2010, 28, 1813-1820. | 1.6 | 145 |
| 63 | High-resolution genomic and expression analyses of copy number alterations in <i>HER2</i> -amplified breast cancer. <i>Breast Cancer Research</i> , 2010, 12, R25. | 5.0 | 123 |
| 64 | Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with <i>BRCA1</i> or <i>BRCA2</i> mutations and advanced breast cancer: a proof-of-concept trial. <i>Lancet</i> , The, 2010, 376, 235-244. | 13.7 | 1,584 |
| 65 | Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with <i>BRCA1</i> or <i>BRCA2</i> mutations and recurrent ovarian cancer: a proof-of-concept trial. <i>Lancet</i> , The, 2010, 376, 245-251. | 13.7 | 1,596 |
| 66 | Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics. <i>Breast Cancer Research</i> , 2010, 12, R42. | 5.0 | 167 |
| 67 | Cancer incidence in relatives of a population-based set of cases of early-onset breast cancer with a known <i>BRCA1</i> and <i>BRCA2</i> mutation status. <i>Breast Cancer Research</i> , 2003, 5, R175-86. | 5.0 | 37 |
| 68 | Molecular classification of familial non- <i>BRCA1/BRCA2</i> breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 2532-2537. | 7.1 | 182 |
| 69 | Gene-Expression Profiles in Hereditary Breast Cancer. <i>New England Journal of Medicine</i> , 2001, 344, 539-548. | 27.0 | 1,669 |
| 70 | Deletion mapping of chromosome segment 11q24-q25, exhibiting extensive allelic loss in early onset breast cancer. <i>International Journal of Cancer</i> , 2001, 92, 208-213. | 5.1 | 18 |
| 71 | Reproductive factors in hereditary breast cancer. <i>Breast Cancer Research and Treatment</i> , 1999, 58, 293-299. | 2.5 | 16 |
| 72 | Somatic genetic alterations in <i>BRCA2</i> -associated and sporadic male breast cancer. <i>Genes Chromosomes and Cancer</i> , 1999, 24, 56-61. | 2.8 | 50 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 73 | Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. <i>Cancer</i> , 1998, 83, 310-319. | 4.1 | 170 |
| 74 | Analysis of Swedish male breast cancer family data: A simple way to incorporate a common sibling effect. , 1998, 15, 201-212. | | 5 |
| 75 | Pregnancy-associated breast cancer in BRCA1 and BRCA2 germline mutation carriers. <i>Lancet, The</i> , 1998, 352, 1359-1360. | 13.7 | 111 |
| 76 | Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. <i>Cancer</i> , 1998, 83, 310-319. | 4.1 | 2 |
| 77 | Phospholipase C Coupled G-Proteins: Molecular Targets of Ethanol. , 1993, , 235-244. | | 1 |
| 78 | G Proteins Coupled to Phospholipase C: Molecular Targets of Long-Term Ethanol Exposure. <i>Journal of Neurochemistry</i> , 1991, 56, 2018-2026. | 3.9 | 31 |